Viatris’ First-Ever Interchangeable Insulin Biosimilar Preferred on Express Scripts’ Largest Formulary

PITTSBURGH , Oct. 20, 2021 /PRNewswire/ — Viatris Inc. (NASDAQ: VTRS ) is proud to confirm that Express Scripts, a leading pharmacy benefit management organization, will list Viatris’ interchangeable biosimilar Semglee ® (insulin glargine-yfgn) injection as a preferred insulin brand on its National Preferred Formulary ® (NPF), which includes more than 28 million lives.

Read the source article at PR Newswire
2021-10-20 19:37:00